You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 207691 - 207700 of 207712 results
  1. A2A AR Agonists as Adjunct Therapy Against S. aureus Sepsis

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This is a phase I STTR application to study the efficacy of selective adenosine A2A receptor (A2AR) agonists developed in the laboratories of Adenosine Therapeutics (ATL) in models of Gram-positive bacterial sepsis which will be conducted in the University of Virginia (UVA) laboratories of Dr. Michael Scheld, an expert in the field of infectious disease. Sepsis ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  2. AAAPT Technology for Improving Chemotherapy

    SBC: SCI-ENGI-MEDCO SOLUTIONS, INC            Topic: NCI

    DESCRIPTION provided by applicant Dysregulation of apoptosis pathways and loss of Human Beta Defensin hBD are the common tactics adapted by cancer cells to circumvent the effects of chemotherapy Consequently high dose of chemotherapy is required to obtain a clinically relevant therapeutic index which in turn compromises safety and develops resistance to therapy The problem is acute p ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. A2a Adenosine Receptors and Equine Sepsis

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    NON-TECHNICAL SUMMARY: This is a phase I SBIR proposal by Adenosine Therapeutics for 6 months of support to synthesize and evaluate novel compounds as agonists of equine A2A adenosine receptors. Some of these compounds have been found to be very effective in reducing rodent mortality form endotoxin or from E. coli-induced sepsis. Circulating endotoxin (lipopolysaccharide) is correlated with the pr ...

    SBIR Phase I 2003 Department of Agriculture
  4. A2A Adenosine Receptors and Equine Sepsis

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    Endotoxemia (Sepsis) affects horses of all breeds and ages and is the leading causes of death in adult horses and foals. Consequently, its economic impact on the equine industry in the United States is devastating. This project seeks to develop new treatments for this disease.

    SBIR Phase II 2006 Department of Agriculture
  5. A2A Adenosine Receptor Agonist for the Treatment of IBD

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Adenosine Therapeutics, LLC (ATL) is a biotechnology company started in Charlottesville, Virginia in 1999. ATL owns patents on the formulation and use of a family of potent and highly selective agonists of A2A adenosin

    SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  6. A2a Adenosine Blockers for Parkinson's Disease

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (PROVIDED BY APPLICANT): Selective antagonists of A2A adenosine receptors have proven to be effective for the treatment of Parkinson's disease (PD) both in animal models and in a human trial. However, the initial clinical trial was stopped in phase 3 due to detection of animal toxicity of KW6002. Other investigational compounds lack sufficient potency, selectivity or bioavailability to ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  7. A2a Adenosine Blockers for Parkinson's Disease

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (PROVIDED BY APPLICANT): Selective antagonists of A2A adenosine receptors have proven to be effective for the treatment of Parkinson's disease (PD) both in animal models and in a human trial. However, the initial clinical trial was stopped in phase 3 due to detection of animal toxicity of KW6002. Other investigational compounds lack sufficient potency, selectivity or bioavailability to ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  8. A2A ADENOSINE AGONISTS LIMIT DAMAGE FROM INFECTION

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    epsis syndrome is the 11th leading cause of death in the United States ( about 900,000 new cases per year) with a mortality of about 35 percent. The need for adjunctive therapies is urgent. In Phase I of this SBIR award we documented the anti-inflammatory effects of adenosine A2A receptor (A2AAR) agonists on isolated immune cells and have observed ramatically improved survival in mouse models of I ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  9. A2A ADENOSINE AGONISTS LIMIT DAMAGE FROM INFECTION

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    epsis syndrome is the 11th leading cause of death in the United States ( about 900,000 new cases per year) with a mortality of about 35 percent. The need for adjunctive therapies is urgent. In Phase I of this SBIR award we documented the anti-inflammatory effects of adenosine A2A receptor (A2AAR) agonists on isolated immune cells and have observed ramatically improved survival in mouse models of I ...

    STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  10. A2a Adenosine Agonists for Diabetic Nephropathy

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Diabetic nephropathy (DN) accounts for approximately 40% of the cases of renal failure requiring dialysis or transplantation. Moreover, diabetic nephropathy is associated with markedly higher morbidity and mortality rates. It is important to develop novel interventions to prevent complications of diabetes. Inflammation in the genesis of diabetes, as well as its ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government